Depression is a major medical condition and severe refractory depression is a difficult condition to treat. Electroconvulsive therapy may treat refractory depression but has limitations in access and cost. Join host, Geoff Wall, as he evaluates ketamine as a treatment option for severe depression.
 
The GameChanger
Ketamine has been shown to treat depression and was recently compared to ECT in a non-inferiority trial. Relapse rates and adverse drug reaction rates between treatments were similar.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med. 2023 Jun 22;388(25):2315-2325. doi: 10.1056/NEJMoa2302399. Epub 2023 May 24. PMID: 37224232.

https://www.nejm.org/doi/full/10.1056/NEJMoa2302399

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the history and barriers of ECT for severe depression
2. Describe the results of ketamine vs ECT in depression

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-248-H01-P
Initial release date: 7/24/2023
Expiration date: 7/24/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram